Eli Lilly releases results from dulaglutide's sixth AWARD trial
Eli Lilly released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c) across both arms. The head-to-head study compared the safety and efficacy of dulaglutide and liraglutide, two glucagon-like peptide-1, GLP-1, receptor agonists. These results will be presented at the 74th American Diabetes Association Scientific Sessions in San Francisco.
Terms and Privacy Policy